George Lundberg, MD Editor in Chief at Cancer Commons

  •   George Lundberg, MD

    As reported by Healio, immunotherapy followed by targeted therapy improved overall survival in a clinical trial with metastatic melanoma patients.

    .

  •   George Lundberg, MD

    Clinical trials can be of great importance for patients with cancer. Here is some sound background information from Cancer Commons partner Let’s Win! Pancreatic Cancer.

    .

  •   George Lundberg, MD

    Coping with a potentially lethal cancer presents many serious challenges. This article from Cancer Commons partner Let’s Win! Pancreatic Cancer might help.

    .

  •   George Lundberg, MD

    This clinical case study published in the scientific journal Cureus suggests that intelligent, compassionate, palliative care is likely the best approach to this very difficult brain tumor.

    .

  •   George Lundberg, MD

    As announced by Cancer Commons partner the Musella Foundation For Brain Tumor Research & Information, Inc., a collaboration of groups has announced funding to support research into possible treatments for pediatric diffuse intrinsic pontine glioma (DIPG).

    .

  •   George Lundberg, MD

    As outlined in this press release on PR Newswire, it is now possible to buy many expensive drugs at very inexpensive prices from a new online pharmacy.

    .

  •   George Lundberg, MD

    This Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.

    .

  •   George Lundberg, MD

    This story from The ASCO Post discusses how doctors can help ensure that patients have realistic expectations about outcomes after prostate cancer treatment.

    .

  •   George Lundberg, MD

    According to this article from the Cochrane Database of Systematic Reviews, chemotherapy administered before surgery may be beneficial for people with advanced ovarian cancer.

    .

  •   George Lundberg, MD

    Recently approved by the U.S. Food and Drug Administration (FDA), the drug Cytalux is given to ovarian cancer patients to allow surgeons to recognize cancer cells more clearly, promoting more complete surgical removal of tumors. Learn more in this story from The Philadelphia Inquirer.

    .